"For the quarter ended September 30, 2015, Paratek
Post# of 36
Posted On: 11/17/2015 10:44:07 AM
Re: ProCapital #21
"For the quarter ended September 30, 2015, Paratek reported a net loss attributable to common stockholders of $23.4 million, or $1.33 per share, compared to a net loss attributable to common stockholders of $4.0 million, or $29.48 per share, for the same quarter in 2014.
Research and development expenses for the quarter ended September 30, 2015 were $17.8 million, an increase of $16.8 million compared to the same quarter in 2014. The increase is primarily the result of initiation of the company's Phase 3 clinical trials of omadacycline and includes CRO fees, investigator fees and costs associated with clinical sites and laboratories of $12.1 million, manufacturing of clinical material and registration batches of $3.8 million, and personnel-related costs of $1.1 million.
General and administrative expenses for the quarter ended September 30, 2015 were $5.8 million, a $3.7 million increase compared to the same quarter in 2014, primarily due to the growth in corporate infrastructure to support a public company. Salaries and benefits, including stock-based compensation, increased $1.5 million compared to the same quarter in 2014. Professional and consulting fees increased $0.4 million compared to the same quarter in 2014 primarily due to higher legal, finance and accounting, and market research costs.
As of September 30, 2015, Paratek had cash and cash equivalents of $146.4 million, which is expected to fund operations through top-line results from the Phase 3 study of omadacycline for CABP, projected to be available in the second half of 2017."
http://www.otcmarkets.com/stock/PRTK/news
Research and development expenses for the quarter ended September 30, 2015 were $17.8 million, an increase of $16.8 million compared to the same quarter in 2014. The increase is primarily the result of initiation of the company's Phase 3 clinical trials of omadacycline and includes CRO fees, investigator fees and costs associated with clinical sites and laboratories of $12.1 million, manufacturing of clinical material and registration batches of $3.8 million, and personnel-related costs of $1.1 million.
General and administrative expenses for the quarter ended September 30, 2015 were $5.8 million, a $3.7 million increase compared to the same quarter in 2014, primarily due to the growth in corporate infrastructure to support a public company. Salaries and benefits, including stock-based compensation, increased $1.5 million compared to the same quarter in 2014. Professional and consulting fees increased $0.4 million compared to the same quarter in 2014 primarily due to higher legal, finance and accounting, and market research costs.
As of September 30, 2015, Paratek had cash and cash equivalents of $146.4 million, which is expected to fund operations through top-line results from the Phase 3 study of omadacycline for CABP, projected to be available in the second half of 2017."
http://www.otcmarkets.com/stock/PRTK/news
(0)
(0)